Detection of hepatocellular carcinoma using 11C-choline PET: Comparison with 18F-FDG PET

Journal of Nuclear Medicine

Volumn 49, Issue 8, 2008, Pages 1245-1248

  Yamamoto, Yuka ^a   Nishiyama, Yoshihiro ^a   Kameyama, Reiko ^a   Okano, Keiichi ^a   Kashiwagi, Hirotaka ^a   Deguchi, Akihiro ^a   Kaji, Masato ^b   Ohkawa, Motoomi ^a  

^a KAGAWA UNIVERSITY   (Japan)

^b KAGAWA UNIVERSITY HOSPITAL   (Japan)

Author keywords

11C choline; 18F FDG; Hepatocellular carcinoma; PET

Indexed keywords

CHOLINE CARBON 11; FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CALCULATION; CANCER DIAGNOSIS; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DRUG UPTAKE; FEMALE; HUMAN; LIVER; LIVER CELL CARCINOMA; MALE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RETROSPECTIVE STUDY;

AGED; CARBON RADIOISOTOPES; CARCINOMA, HEPATOCELLULAR; CHOLINE; FEASIBILITY STUDIES; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES;

EID: 48749105645     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.108.052639     Document Type: Article

References (20)

1. Rohren EM, Turkington TG, Coleman RE. Clinical applications of PET in oncology. Radiology. 2004;231:305-332.
2. Iwata Y, Shiomi S, Sasaki N, et al. Clinical usefulness of positron emission tomography with fluorine-18-fluorodeoxyglucose in the diagnosis of liver tumors. Ann Nucl Med. 2000;14:121-126.
3. Khan M, Combs C, Brunt E, et al. Positron emission tomography scanning in the evaluation of hepatocellular carcinoma. J Hepatol. 2000;32:792-797.
4. Torizuka T, Tamaki N, Inokuma T, et al. In vivo assessment of glucose metabolism in hepatocellular carcinoma with FDG-PET. J Nucl Med. 1995;36:1811-1817.
5. 11C]choline. J Nucl Med. 1997;38:842-847.
6. Hara T, Kosaka N, Kishi H. PET imaging of prostate cancer using carbon-11-choline. J Nucl Med. 1998;39:990-995.
7. 11C-choline PET. J Nucl Med. 2000;41:1507-1513.
8. 18F-FDGPET. J Nucl Med. 2003;44:1051-1056.
9. 11C]choline, implications for in vivo imaging with positron emission tomography. Eur J Nucl Med. 2000;27:25-32.
10. Podo F. Tumor phospholipids metabolism. NMR Biomed. 1999;12:413-439.
11. Edmondson HA, Steiner PE. Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies. Cancer. 1954;7:462-503.
12. 11C]choline. J Labelled Comp Radiopharm. 2000;43:195-203.
13. 18F]fluoro-D-glucose by direct nucleophilic exchange on a quaternary 4-aminopyridinium resin. Int J Rad Appl Instrum B. 1990;17:273-279.
14. Delbeke D, Martin WH, Sadler MP, Chapman WC, Wright JK Jr, Pinson CW. Evaluation of benign vs malignant hepatic lesions with positron emission tomography. Arch Surg. 1998;133:510-516.
15. Huebner RH, Park KC, Shepherd JE, et al. A meta-analysis of the literature for whole-body FDG PET detection of recurrent colorectal cancer. J Nucl Med. 2000;41:1177-1189.
16. Trojan J, Schroeder O, Raedle J, et al. Fluorine-18 FDG positron emission tomography for imaging of hepatocellular carcinoma. Am J Gastroenterol. 1999;94:3314-3319.
17. Okazumi S, Isono K, Enomoto K, et al. Evaluation of liver tumors using fluorine-18-fluorodeoxyglucose PET: characterization of tumor and assessment of effect of treatment. J Nucl Med. 1992;33:333-339.
18. 18F]FDG PET/CT. Eur J Nucl Med Mol Imaging. 2006;33:1285-1289.
19. 11C-acetate PET imaging in hepatocellular carcinoma and other liver masses. J Nucl Med. 2003;44:213-221.
20. Ho CL, Chen S, Yeung DW, Cheng TK. Dual-tracer PET/CT imaging in evaluation of metastatic hepatocellular carcinoma. J Nucl Med. 2007;48:902-909.